Apocynin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Apocynin
Accession Number
DB12618
Type
Small Molecule
Groups
Investigational
Description

Acetovanillone has been used in trials studying the treatment of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.

Structure
Thumb
Synonyms
  • Acetovanillone
Categories
UNII
B6J7B9UDTR
CAS number
498-02-2
Weight
Average: 166.1739
Monoisotopic: 166.062994186
Chemical Formula
C9H10O3
InChI Key
DFYRUELUNQRZTB-UHFFFAOYSA-N
InChI
InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3
IUPAC Name
1-(4-hydroxy-3-methoxyphenyl)ethan-1-one
SMILES
COC1=C(O)C=CC(=C1)C(C)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with 5-androstenedione.Experimental, Illicit
AbciximabApocynin may increase the anticoagulant activities of Abciximab.Approved
AcebutololApocynin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Apocynin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Apocynin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolApocynin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Apocynin.Approved, Vet Approved
AclarubicinApocynin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Apocynin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Apocynin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinApocynin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Alendronic acid.Approved
AliskirenApocynin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Alminoprofen.Experimental
AlprenololApocynin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Apocynin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Amcinonide.Approved
AmikacinApocynin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideApocynin may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinApocynin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodApocynin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Apocynin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Apocynin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Apocynin.Investigational
AnnamycinApocynin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Apocynin.Approved
Antithrombin III humanApocynin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApocynin may increase the anticoagulant activities of Apixaban.Approved
ApramycinApocynin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Apocynin.Approved, Investigational
ArbekacinApocynin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinApocynin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanApocynin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololApocynin may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Apocynin is combined with Atamestane.Investigational
AtenololApocynin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Apocynin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Apocynin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apocynin.Approved
BalsalazideApocynin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminApocynin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololApocynin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinApocynin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Apocynin.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Apocynin is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Apocynin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Apocynin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Apocynin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Apocynin is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Apocynin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Betamethasone.Approved, Vet Approved
BetaxololApocynin may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Apocynin.Approved, Investigational
BevantololApocynin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Apocynin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Apocynin.Approved, Investigational
BisoprololApocynin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinApocynin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololApocynin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Apocynin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Apocynin.Investigational
BucindololApocynin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Apocynin is combined with Bufexamac.Experimental
BufuralolApocynin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Bumadizone.Experimental
BumetanideApocynin may decrease the diuretic activities of Bumetanide.Approved
BupranololApocynin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Apocynin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Apocynin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Apocynin.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Apocynin.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Apocynin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Apocynin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Apocynin.Approved, Vet Approved, Withdrawn
CarteololApocynin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolApocynin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Apocynin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Apocynin.Approved, Investigational
CeliprololApocynin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinApocynin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Apocynin.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apocynin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Apocynin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Apocynin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apocynin.Approved
CinoxacinApocynin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidApocynin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Apocynin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Apocynin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Apocynin.Vet Approved
CloranololApocynin may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Apocynin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Apocynin.Experimental
CyclosporineApocynin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateApocynin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinApocynin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidApocynin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanApocynin may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinApocynin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Apocynin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Apocynin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Apocynin.Experimental
DesirudinApocynin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Apocynin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Apocynin.Approved, Investigational
DextranApocynin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Apocynin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Apocynin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Apocynin may increase the anticoagulant activities of Dextran 75.Approved
DibekacinApocynin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Apocynin.Approved, Vet Approved
DicoumarolApocynin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Apocynin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Apocynin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Apocynin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Apocynin.Approved
DihydrostreptomycinApocynin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Apocynin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Apocynin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Apocynin.Approved
DoxorubicinApocynin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneApocynin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Apocynin.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Apocynin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Apocynin.Investigational
Edetic AcidApocynin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanApocynin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Apocynin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Apocynin.Approved
EnoxacinApocynin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinApocynin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Apocynin.Experimental
EpanololApocynin may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Apocynin.Approved
EpirubicinApocynin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneApocynin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Apocynin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apocynin.Approved
EquileninThe risk or severity of adverse effects can be increased when Apocynin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Apocynin is combined with Equilin.Approved
EsmololApocynin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Apocynin is combined with Estrone sulfate.Approved
Etacrynic acidApocynin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Apocynin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Apocynin is combined with Ethenzamide.Experimental
Ethyl biscoumacetateApocynin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Apocynin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Apocynin.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Apocynin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Apocynin.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Apocynin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Apocynin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Apocynin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Apocynin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Apocynin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Apocynin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Feprazone.Experimental
Ferulic acidApocynin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Apocynin.Approved, Investigational
FleroxacinApocynin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Apocynin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fludrocortisone.Approved
FluindioneApocynin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineApocynin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Apocynin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Apocynin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Apocynin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Apocynin.Approved, Nutraceutical, Vet Approved
FondaparinuxApocynin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumApocynin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Apocynin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Apocynin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apocynin.Approved
FramycetinApocynin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideApocynin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateApocynin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinApocynin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinApocynin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Apocynin.Approved, Withdrawn
GemifloxacinApocynin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinApocynin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinApocynin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AApocynin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Apocynin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinApocynin may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Apocynin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Apocynin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Apocynin is combined with HE3286.Investigational
HeparinApocynin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Apocynin is combined with Higenamine.Investigational
HydralazineApocynin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Apocynin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Apocynin.Approved, Investigational
Hygromycin BApocynin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Apocynin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Apocynin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Apocynin.Approved
IdarubicinApocynin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxApocynin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apocynin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Apocynin.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Apocynin is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Apocynin.Approved
IndenololApocynin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Apocynin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Apocynin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Apocynin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apocynin.Approved, Investigational
IsepamicinApocynin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Apocynin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Apocynin is combined with Istaroxime.Investigational
KanamycinApocynin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Apocynin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Apocynin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Apocynin.Approved
LabetalolApocynin may decrease the antihypertensive activities of Labetalol.Approved
LandiololApocynin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Apocynin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Apocynin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Apocynin.Approved, Investigational
LepirudinApocynin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanApocynin may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololApocynin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinApocynin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Apocynin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Apocynin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Apocynin.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Apocynin.Approved
LonazolacThe risk or severity of adverse effects can be increased when Apocynin is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Apocynin.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Apocynin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Apocynin is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Apocynin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Apocynin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Apocynin.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Apocynin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Apocynin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Apocynin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Apocynin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apocynin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Apocynin.Approved
MelagatranApocynin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Apocynin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Apocynin.Approved, Vet Approved
MepindololApocynin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineApocynin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Apocynin.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Apocynin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apocynin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololApocynin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Apocynin.Approved
MetoprololApocynin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideApocynin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinApocynin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Apocynin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Apocynin.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Apocynin.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Apocynin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Apocynin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apocynin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Apocynin.Approved
NadololApocynin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinApocynin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatApocynin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Apocynin.Approved
Nalidixic AcidApocynin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Apocynin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Apocynin is combined with NCX 1022.Investigational
NeamineApocynin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololApocynin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinApocynin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinApocynin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Apocynin.Approved
NetilmicinApocynin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Apocynin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apocynin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apocynin.Investigational
NorfloxacinApocynin may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apocynin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apocynin.Approved
OlsalazineApocynin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Apocynin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Apocynin.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Apocynin.Vet Approved
OtamixabanApocynin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Apocynin.Approved
Oxolinic acidApocynin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololApocynin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apocynin.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Apocynin.Approved
ParomomycinApocynin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Parthenolide.Investigational
PazufloxacinApocynin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinApocynin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololApocynin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateApocynin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateApocynin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Apocynin.Approved
PhenindioneApocynin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonApocynin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Apocynin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apocynin.Approved, Investigational
PindololApocynin may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidApocynin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinApocynin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideApocynin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apocynin.Approved, Investigational
Piromidic acidApocynin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Apocynin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Pirprofen.Experimental
Platelet Activating FactorApocynin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinApocynin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinApocynin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Apocynin.Approved
PractololApocynin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Apocynin.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Apocynin can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Apocynin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Apocynin.Approved, Investigational
PropranololApocynin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Apocynin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Apocynin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Apocynin.Vet Approved
Protein CApocynin may increase the anticoagulant activities of Protein C.Approved
Protein S humanApocynin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeApocynin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinApocynin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Apocynin.Investigational
PuromycinApocynin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Apocynin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Apocynin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Apocynin.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Apocynin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apocynin.Approved, Experimental, Investigational
ReviparinApocynin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinApocynin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Risedronate.Approved, Investigational
RivaroxabanApocynin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Apocynin.Investigational, Withdrawn
RosoxacinApocynin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinApocynin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinApocynin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Apocynin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Apocynin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Apocynin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Apocynin.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apocynin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Apocynin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Apocynin.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Apocynin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Apocynin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Apocynin is combined with Serrapeptase.Investigational
SisomicinApocynin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinApocynin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Apocynin.Approved
SotalolApocynin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CApocynin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinApocynin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinApocynin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Apocynin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Apocynin.Investigational
StreptomycinApocynin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinApocynin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Apocynin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Apocynin.Approved
SulodexideApocynin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Apocynin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Apocynin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Suxibuzone.Experimental
TacrolimusApocynin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Apocynin.Approved
TalinololApocynin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Apocynin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Apocynin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Apocynin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apocynin.Approved, Investigational
TemafloxacinApocynin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Apocynin.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Apocynin is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Apocynin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Apocynin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Apocynin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Apocynin.Approved
TertatololApocynin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Apocynin.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololApocynin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Apocynin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Apocynin is combined with Tixocortol.Approved, Withdrawn
TobramycinApocynin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Apocynin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Apocynin.Approved
TorasemideApocynin may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Apocynin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Apocynin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apocynin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Apocynin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneApocynin may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Apocynin is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Apocynin.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Apocynin.Investigational
TrovafloxacinApocynin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinApocynin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Apocynin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Apocynin.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Apocynin.Investigational, Withdrawn
ValrubicinApocynin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Apocynin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Apocynin.Approved
WarfarinApocynin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranApocynin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Apocynin.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Apocynin.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Apocynin.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apocynin.Withdrawn
Zoptarelin doxorubicinApocynin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinApocynin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11380
PubChem Compound
2214
PubChem Substance
347828831
ChemSpider
21106900
ChEBI
2781
ChEMBL
CHEMBL346919
HET
I75
PDB Entries
3tbc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBronchial Asthma1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.04 mg/mLALOGPS
logP1.62ALOGPS
logP1.07ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)8.27ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.9 m3·mol-1ChemAxon
Polarizability16.95 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-4900000000-17a85dc123d088c3aa49
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Methoxyphenols / Acetophenones / Phenoxy compounds / Methoxybenzenes / Benzoyl derivatives / Aryl alkyl ketones / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Organic oxides
show 1 more
Substituents
Alkyl-phenylketone / Methoxyphenol / Acetophenone / Phenoxy compound / Methoxybenzene / Aryl alkyl ketone / Anisole / Phenol ether / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid
show 8 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
methyl ketone, aromatic ketone, acetophenones (CHEBI:2781) / Flavans, Flavanols and Leucoanthocyanidins (C11380)

Drug created on October 20, 2016 17:14 / Updated on December 01, 2017 16:31